Tarsus Pharmaceuticals Inc (TARS)
26.42
+0.34
(+1.30%)
USD |
NASDAQ |
Jun 24, 16:00
27.99
+1.57
(+5.94%)
After-Hours: 20:00
Tarsus Pharmaceuticals Revenue (Quarterly): 27.61M for March 31, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 27.61M |
| December 31, 2023 | 13.08M |
| September 30, 2023 | 1.871M |
| June 30, 2023 | |
| March 31, 2023 | 2.50M |
| December 31, 2022 | 10.00M |
| September 30, 2022 |
| Date | Value |
|---|---|
| June 30, 2022 | 15.28M |
| March 31, 2022 | 0.539M |
| December 31, 2021 | 0.338M |
| September 30, 2021 | 1.24M |
| June 30, 2021 | 22.02M |
| March 31, 2021 | 33.43M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
0.338M
Minimum
Dec 2021
33.43M
Maximum
Mar 2021
11.63M
Average
10.00M
Median
Dec 2022
Revenue (Quarterly) Benchmarks
| Pacira BioSciences Inc | 167.12M |
| CEL-SCI Corp | -- |
| AIM ImmunoTech Inc | 0.04M |
| IGC Pharma Inc | 0.204M |
| NovaBay Pharmaceuticals Inc | 2.631M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -35.73M |
| Total Expenses (Quarterly) | 65.30M |
| EPS Diluted (Quarterly) | -1.01 |
| Enterprise Value | 729.60M |
| Gross Profit Margin (Quarterly) | 94.01% |
| Profit Margin (Quarterly) | -129.4% |
| Earnings Yield | -18.05% |
| Normalized Earnings Yield | -18.02 |